Honokiol inhibits hypoxia-inducible factor-1 pathway

International Journal of Radiation Biology

Volumn 87, Issue 6, 2011, Pages 579-590

  Lan, Keng Li ^a   Lan, Keng Hsin ^a,b   Sheu, Meei Ling ^c   Chen, Ming Yuan ^a   Shih, Yi Sheng ^a   Hsu, Fu Chih ^a   Wang, Hong Ming ^a   Liu, Ren Shyan ^a,b   Yen, Sang Hue ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

honokiol; Hypoxia inducible factor 1 (HIF 1 ); hypoxia responsive element (HRE)

Indexed keywords

ANTINEOPLASTIC AGENT; COBALT CHLORIDE; HONOKIOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; MESSENGER RNA; RADIOSENSITIZING AGENT; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME INHIBITION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; HYPOXIA; IC 50; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIPHENYL COMPOUNDS; COBALT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; LIGNANS; LUCIFERASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS;

ANIMALIA; MURINAE; MUS;

EID: 79958066525     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2011.568572     Document Type: Article

References (41)

1. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. 2003. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumour growth in vivo. Journal of Biological Chemistry 278:35501-35507. (Pubitemid 37102321)
2. Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Hsien Lee Y, Lin S. 2003. GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochemical and Biophysical Research Communications 302:95-100. (Pubitemid 36268924)
3. Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, Hu X. 2004. Honokiol: A potent chemotherapy candidate for human colorectal carcinoma. World Journal of Gastroenterology 10: 3459-3463. (Pubitemid 39549546)
4. Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE. 1999. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. Journal of Biological Chemistry 274:33709-33713. (Pubitemid 129511686)
5. Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. 2009. Honokiol-mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. Journal of Immunotherapy 32:585-592.
6. Dewhirst MW, Cao Y, Moeller B. 2008. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer 8:425-437. (Pubitemid 351744964)
7. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. 1999. Noninvasive assessment of tumour cell proliferation in animal models. Neoplasia 1:303-310.
8. Fu B, Xue J, Li Z, Shi X, Jiang BH, Fang J. 2007. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Molecular Cancer Therapy 6:220-226. (Pubitemid 46206685)
9. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 277:38205-38211. (Pubitemid 35154674)
10. Giaccia A, Siim BG, Johnson RS. 2003. HIF-1 as a target for drug development. Nature Reviews Drug Discovery 2:803-811. (Pubitemid 37361812)
11. Hahm ER, Arlotti JA, Marynowski SW, Singh SV. 2008. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clinical Cancer Research 14:1248-1257. (Pubitemid 351302574)
12. Hibasami H, Achiwa Y, Katsuzaki H, Imai K, Yoshioka K, Nakanishi K, Ishii Y, Hasegawa M, Komiya T. 1998. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. International Journal of Molecular Medicine 2:671-673.
13. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth and Differentiation 12:363-369. (Pubitemid 32685637)
14. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G. 2005. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNAbinding activity. Cancer Research 65:9047-9055. (Pubitemid 41377397)
15. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. 2010. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumour effects of epidermal growth factor receptor inhibitors. Clinical Cancer Research 16:2571-2579.
16. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. 2004. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10:594-601. (Pubitemid 38796850)
17. Moeller BJ, Cao Y, Li CY, Dewhirst MW. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumours: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441. (Pubitemid 38610245)
18. Nagase H, Ikeda K, Sakai Y. 2001. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Medica 67:705-708. (Pubitemid 33044474)
19. Neckers L. 2002. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends in Molecular Medicine 8:S55-61. (Pubitemid 34297080)
20. Palfreyman MG. 2002. Human tissue in target identification and drug discovery. Drug Discovery Today 7:407-409. (Pubitemid 34251106)
21. Park EJ,MinHY, ChungHJ, Hong JY,Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK. 2009. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB- 231 human breast cancer cells. Cancer Letters 277:133-140.
22. Rankin EB, Giaccia AJ. 2008. The role of hypoxia-inducible factors in tumourigenesis. Cell Death and Differentiation 15:678-685.
23. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. 2004. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Research 64:1475-1482. (Pubitemid 38235619)
24. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na, II, Yang SH, Kim CH, Yoo YD, Lee JC. 2009. Gefitinib circumvents hypoxiainduced drug resistance by the modulation of HIF-1alpha. Oncology Reports 21:801-807.
25. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3(10):721-732. (Pubitemid 37328811)
26. Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
27. Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW. 2007. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109:1279-1289. (Pubitemid 46466554)
28. Shinohara ET, Maity A. 2009. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumour microenvironment. Current Molecular Medicine 9:1034-1045.
29. Sodhi A, Montaner S, Miyazaki H, Gutkind JS. 2001. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochemical and Biophysical Research Communications 287:292-300. (Pubitemid 32912498)
30. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH. 1999. Visualizing the kinetics of tumour-cell clearance in living animals. Proceedings of the National Academy of Sciences of the USA 96:12044-12049. (Pubitemid 29502855)
31. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson, JJ, Pereira MM, Nicolaou KC, Van Meir EG. 2005. Identification of a novel small-molecule inhibitor of the hypoxiainducible factor 1 pathway. Cancer Research 65:605-612.
32. Tsai TH, Chou CJ, Cheng FC, Chen CF. 1994. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 655:41-45.
33. Tse AK, Wan CK, Shen XL, Yang M, Fong WF. 2005. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochemical Pharmacology 70:1443-1457. (Pubitemid 41483455)
34. Wang T, Chen F, Chen Z, Wu YF, Xu XL, Zheng S, Hu X. 2004. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World Journal of Gastroenterology 10:2205-2208. (Pubitemid 39144968)
35. Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP. 2007. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. International Journal of Oncology 30:1529-1537.
36. Won MS, Im N, Park S, Boovanahalli SK, Jin Y, Jin X, Chung KS, Kang M, Lee K, Park SK and others. 2009. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochemical and Biophysical Research Communications 385:16-21.
37. Xu D, Lu Q, Hu X. 2006. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Letters 243:274-280. (Pubitemid 44485849)
38. Yang SE, Hsieh MT, Tsai TH, Hsu SL. 2002. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochemical Pharmacology 63:1641-1651.
39. Zhong H, Willard M, Simons J. 2004. NS398 reduces hypoxiainducible factor (HIF)- 1alpha and HIF-1 activity: multiplelevel effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer 112: 585-595. (Pubitemid 39425938)
40. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/ FRAP pathway in human prostate cancer cells: Implications for tumour angiogenesis and therapeutics. Cancer Research 60:1541-1545. (Pubitemid 30183422)
41. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 14:391-396. (Pubitemid 30131884)